Emmes Group, a global CRO, has entered into a partnership with Miimansa AI to leverage the company’s Clinical Entity Modelling tools for the optimisation of its clinical research programme.
The acquisition of Miimansa AI’s modelling tools will work to accelerate the development of automated text processing technologies specifically designed for clinical research.
According to Emmes, the collaboration will allow the company to quickly and accurately process vast amounts of clinical data, while also enabling text to text transformations such as protocol authoring and medical writing — reducing the time and cost associated with manual data handling.
"We are excited to partner with Miimansa AI to bring cutting-edge AI technology to the forefront of clinical research," said Sastry Chilukuri, CEO of Emmes Group. “The clinical entity modelling tools acquired through our partnership will accelerate development and adoption of Emmes Groups’ Gen AI platform to drive faster, better and more efficient clinical trials.”
Dr Vibhu Agarwal, founder and CEO of Miimansa AI, added, "Teaming up with Emmes Group is a significant milestone for us. Together, we aim to transform the landscape of clinical research — making it faster, more affordable and ultimately more successful in delivering safe and effective treatments."
